Pharmacovigilance analysis of neurological adverse events associated with GLP-1 receptor agonists based on the FDA Adverse Event Reporting System

Pharmacovigilance analysis of neurological adverse events associated with GLP-1 receptor agonists based on the FDA Adverse Event Reporting System

Abstract We conducted a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database (2005 Q2–2024 Q3) to evaluate neurological adverse events (NAEs) associated with six glucagon-like peptide-1 receptor agonists (GLP-1 RAs): exenatide, liraglutide, lixisenatide, dulaglutide...

Full description

Saved in:

Bibliographic Details
Main Authors:	He Chen, Sixing Liu, Shuai Gao, Hangyu Shi, Yan Yan, Yixing Xu, Jiufei Fang, Weiming Wang, Huan Chen, Zhishun Liu
Format:	Article
Language:	English
Published:	Nature Portfolio 2025-05-01
Series:	Scientific Reports
Subjects:	Neurological adverse events GLP-1 receptor agonists Pharmacovigilance FAERS database Disproportionality analysis Diabetes
Online Access:	https://doi.org/10.1038/s41598-025-01206-9
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Neurological adverse events associated with baclofen: a pharmacovigilance study based on FDA adverse event reporting system
by: Yunhan Zhao, et al.
Published: (2025-05-01)

A pharmacovigilance study of vortioxetine based on data from the FDA adverse event reporting system
by: Miao Liu, et al.
Published: (2025-08-01)

Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database
by: Chang-Zhu He, et al.
Published: (2025-03-01)

A disproportionality analysis of FDA adverse event reporting system events for misoprostol
by: Li Yang, et al.
Published: (2025-01-01)

Drug-induced kidney stones: a real-world pharmacovigilance study using the FDA adverse event reporting system database
by: Pan Ding, et al.
Published: (2025-03-01)

Neurological adverse events associated with antidepressants: a comprehensive 22-year analysis of the FDA adverse event reporting system
by: Qian Yu, et al.
Published: (2025-08-01)

Drug-induced coagulopathies: a real-world pharmacovigilance study using the FDA adverse event reporting system
by: Yanjun Lu, et al.
Published: (2024-12-01)

A real-world pharmacovigilance study of neuroleptic malignant syndrome based on FDA adverse event reporting system
by: Yu Zhang, et al.
Published: (2024-12-01)

Signal mining and analysis of ripretinib adverse events: a real-world pharmacovigilance analysis based on the FAERS database
by: Ye Hu, et al.
Published: (2025-02-01)

Drug-associated hearing impairment in children: a disproportionality analysis of the FDA adverse event reporting system
by: Jinfeng Liu, et al.
Published: (2025-06-01)

A real-world Pharmacovigilance study of brodalumab based on the FDA adverse event reporting system
by: Ke He, et al.
Published: (2025-01-01)

Safety assessment of ripretinib: a real-world adverse event analysis from the food and drug administration adverse event reporting system
by: Sentai Wang, et al.
Published: (2025-03-01)

Pharmacovigilance of drug-induced cataract using the FDA Adverse Event Reporting System
by: Si-Yuan Hong, et al.
Published: (2025-07-01)

Adverse events associated with gepants: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Qi Song, et al.
Published: (2025-06-01)

Hypoglycemia associated with fluoroquinolone: a pharmacovigilance analysis from 2014 to 2023 based on the FDA adverse event reporting system
by: Dan Li, et al.
Published: (2025-05-01)

Comprehensive analysis of adverse events associated with vortioxetine using the FDA adverse event reporting system
by: Liangxia Li, et al.
Published: (2025-05-01)

A real-world pharmacovigilance analysis of potential ototoxicity associated with sacubitril/valsartan based on FDA Adverse Event Reporting System (FAERS)
by: Ning Wang, et al.
Published: (2024-12-01)

Assessing real-world safety of plecanatide: a pharmacovigilance study based on the FDA adverse event reporting system
by: Zhiyuan Zhang, et al.
Published: (2024-11-01)

Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)
by: Weidong Zhang, et al.
Published: (2025-01-01)

Psychiatric safety associated with hormone replacement therapy for menopausal symptoms: a real-world study of the FDA adverse event reporting system
by: Nan Chen, et al.
Published: (2025-06-01)

Ophthalmic corticosteroids-related adverse events: the FDA adverse event reporting system (FAERS) database pharmacovigilance study
by: Chengzhi Liu, et al.
Published: (2024-12-01)

A real-world pharmacovigilance study of lorazepam based on the FDA adverse event reporting system database
by: Chunyue Fang, et al.
Published: (2025-06-01)

A real-world pharmacovigilance study of netarsudil based on the FDA adverse event reporting system (FAERS)
by: Xiaomei Xiong, et al.
Published: (2025-04-01)

Emerging cardiovascular toxicity associated with CDK4/6 inhibitors: real-world insights from the FDA adverse event reporting system
by: Wensheng Liu, et al.
Published: (2025-05-01)

Glucagon-like peptide-1 receptor agonist-induced cholecystitis and cholelithiasis: a real-world pharmacovigilance analysis using the FAERS database
by: Chao Tao, et al.
Published: (2025-07-01)

The real-world safety of Nivolumab: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Yutong Wu, et al.
Published: (2025-05-01)

The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Yue Zhou, et al.
Published: (2025-01-01)

Post-marketing safety concerns with dolutegravir: a pharmacovigilance study based on the FDA adverse event reporting system database
by: Juan Su, et al.
Published: (2025-07-01)

Pharmacovigilance analysis of polatuzumab plus bendamustine and rituximab treatment protocol: identifying comprehensive safety signals using FDA database
by: Fang Wu, et al.
Published: (2025-02-01)

A real-world pharmacovigilance analysis of omadacycline in FDA adverse event reporting system (FAERS) database
by: Xueping Shi, et al.
Published: (2025-04-01)

Association between GLP-1 RAs and DPP-4 inhibitors with biliary disorders: pharmacovigilance analysis
by: Long He, et al.
Published: (2025-02-01)

Drug-induced pulmonary edema: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS)
by: Zilan Zhong, et al.
Published: (2025-08-01)

Pharmacovigilance study of famciclovir in the Food and Drug administration adverse event reporting system database
by: Runan Fang, et al.
Published: (2024-11-01)

Pharmacovigilance study of drug-induced eye movement disorder based on FDA adverse event reports from 2004 to 2024
by: Si-Yuan Hong, et al.
Published: (2025-07-01)

Updated insights into adverse events associated with mepolizumab: a disproportionality analysis from the FDA adverse event reporting system database
by: Shan Lin, et al.
Published: (2024-10-01)

Disproportionality analysis of adverse events associated with pacritinib: a real-world study based on FDA Adverse Event Reporting System (FAERS) database
by: Huiling Zhang, et al.
Published: (2025-07-01)

A pharmacovigilance study on probiotic preparations based on the FDA Adverse Event Reporting System from 2005 to 2023
by: Yitong Wang, et al.
Published: (2025-05-01)

Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system
by: Shiyi Wang, et al.
Published: (2025-02-01)

Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)
by: Zhuomiao Lin, et al.
Published: (2025-08-01)

Osimertinib-related myotoxicity: a disproportionality analysis of the FDA adverse event reporting system
by: Yaqian Tan, et al.
Published: (2025-08-01)